| Ytd | -15.49% | |
| 1y | 52.54% |
| Open | 3.76 | Prev Close | 3.75 | Low | 3.58 | High | 3.82 | Mkt Cap | 783.73M |
| Vol | 5.57M | Avg Vol | 4.45M | EPS | -0.52 | P/E | N/A | Forward P/E | -9.74 |
| Beta | 2.48 | Short Ratio | 1.78 | Inst. Own | 75.69% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 08-06 | 50-d Avg | 3.63 | 200-d Avg | 4.11 | 1yr Est | 13.67 |
CTMX News
- Expanded collaboration builds upon research momentum in developing next-generation bispecific immu
HC Wainwright & Co. analyst Mitchell S. Kapoor maintains CytomX Therapeutics (NASDAQ:CTMX) wi
CytomX Therapeutics (NASDAQ:CTMX) reported quarterly losses of $(0.10) per share which beat the anal
Piper Sandler analyst Joseph Catanzaro maintains CytomX Therapeutics (NASDAQ:CTMX) with a Overwei
Barclays analyst Etzer Darout maintains CytomX Therapeutics (NASDAQ:CTMX) with a Overweight and r
Jefferies analyst Roger Song maintains CytomX Therapeutics (NASDAQ:CTMX) with a Buy and raises th
CytomX stock falls after $250 million share sale, even as new colorectal cancer data shows strong re
Guggenheim analyst Michael Schmidt maintains CytomX Therapeutics (NASDAQ:CTMX) with a Buy and rai
Wedbush analyst Robert Driscoll maintains CytomX Therapeutics (NASDAQ:CTMX) with a Outperform and
Common StockPreferred StockDebt SecuritiesWarrantsUnitsWe may offer and sell the securities identifi
In addition, CytomX expects to grant the underwriters a 30-day option to purchase up to an additiona
CytomX Therapeutics stock jumps in premarket trading after Phase 1 data for Varseta-M showed tumor r
HC Wainwright & Co. analyst Mitchell S. Kapoor maintains CytomX Therapeutics (NASDAQ:CTMX) wi
JP Morgan analyst Anupam Rama upgrades CytomX Therapeutics (NASDAQ:CTMX) from Neutral to Overweig
Dow Jones index up 500 points; Nebius Group NV shares rise 12.7% on AI agreement with Meta Platforms
NBIS: 17% | Nebius Announced 5-Year $12B AI Infrastructure Agreement With Meta To Provide Dedicated
- Confirmed response rates in expansion cohorts of 32% at 10 mg/kg Q3W dose and 20% at 8.6 mg/kg Q3W
CytomX Therapeutics (NASDAQ:CTMX) reported quarterly losses of $(0.22) per share which missed the an
CytomX Therapeutics (CTMX) will release its Q4 earnings on March 16, with analysts expecting a loss
Guggenheim analyst Michael Schmidt reiterates CytomX Therapeutics (NASDAQ:CTMX) with a Buy and ma
Cantor Fitzgerald analyst Olivia Brayer maintains CytomX Therapeutics (NASDAQ:CTMX) with a Overwe
Barclays analyst Etzer Darout maintains CytomX Therapeutics (NASDAQ:CTMX) with a Overweight and r
Barclays analyst Etzer Darout maintains CytomX Therapeutics (NASDAQ:CTMX) with a Overweight and r
Guggenheim analyst Michael Schmidt initiates coverage on CytomX Therapeutics (NASDAQ:CTMX) with a
Piper Sandler analyst Joseph Catanzaro maintains CytomX Therapeutics (NASDAQ:CTMX) with a Overwei
- CX-2051 (varsetatug masetecan) Phase 1 Colorectal Cancer expansion data on track for Q1 2026 -- Va
HC Wainwright & Co. analyst Mitchell S. Kapoor maintains CytomX Therapeutics (NASDAQ:CTMX) wi
CytomX Therapeutics (NASDAQ:CTMX) reported quarterly losses of $(0.09) per share which missed the an
- CX-801 (PROBODY® interferon alpha-2b) Phase 1 data demonstrate activation of tumor-selective inter
Barclays analyst Etzer Darout maintains CytomX Therapeutics (NASDAQ:CTMX) with a Overweight and r
Gainers Galecto (NASDAQ: GLTO) stock rose 21.6% to $5.41 during Thursday's after-market session
